BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.
BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy. Barron's
Covered in this story
Analyst targets on Moderna
- Citi: at $193 · target $80 by Sep 2027 · Sell via 247wallst.com
- Rothschild & Co Redburn: at $149 · target $81 by Sep 2027 · Sell via Investing.com
- Morgan Stanley: at $174 · target $89 by Aug 2027 · Equalweight via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRNA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Moderna →Dalsna Finance is currently tracking 5 stories mentioning Moderna, the earliest published 20 Aug 2026.
Summary aggregated from Barron's's public RSS feed. The full reporting belongs to Barron's — please read it on their site.